[ET Net News Agency, 18 January 2022] Luye Pharma Group Ltd. (02186) said the marketing
authorization application for the group's analgesic product under development, oxycodone
and naloxone extended-release tablets (LY021702), has been accepted by the Centre for Drug
Evaluation of the National Medical Products Administration in the People's Republic of
China.
LY021702 is the first oxycodone and naloxone extended release tablet product that has
high technical barriers developed by a Chinese company. It consists of oxycodone
hydrochloride, a strong opioid receptor agonist, and naloxone hydrochloride, an opioid
antagonist, for the treatment of moderate to severe chronic pain that cannot be
effectively controlled by non-opioids, with pain relief lasting up to 12 hours. It has a
deterrent feature regarding opioid abuse and can relieve gastrointestinal adverse effects
such as opioid-induced constipation. (RC)